Here is My Question:
What do we know about Ocrevus rebound? Is it like Tysabri?
The short answer is ‘no’. While the experience of Ocrevus is still limited, the similar biological Rituximab, which is given off label for MS suggests no significant rebound coming off these b-cell targeting therapies.
A. Scott Nielsen MD MMSc
Neurologist and MS Specialist at Kaiser Permanente
PLEASE NOTE: This information/opinions on this site should be used as an information source only. This information does not create any patient-HCP relationship, and should not be used as a substitute for professional diagnosis and treatment. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition.